Apeiron Biologics
Vienna
About Apeiron Biologics
APEIRON is a focused on the discovery and development of novel cancer immunotherapies. APEIRON’s lead clinical program APN401 is a first-in-class autologous cellular therapy to enhanc immune reactivity via an intracellular immune master checkpoint, Cbl-b. APEIRON’s key projects and technologies are bolstered by a strong patent portfolio with broad territorial coverage. APEIRON’s development expertise is validated through partnerships with leading global pharmaceutical companies and academic institutions.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $29.9M
- Funding stage: M&A
- Last round: Corporate Round (May 2020)
- Website: apeiron-biologics.com
- Phone: +43 1 86565 77
Industries & Categories
Biotechnology, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/apeiron-biologics-58410 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.